Merck & Company Inc.

News & Events

Press Releases

In The Media

1. Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference

   Business Wire MAY 22, 2025 6:45 AM EDT
   Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Rob...
   READ ARTICLE

2. IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

   Business Wire MAY 19, 2025 7:00 AM EDT
   The first patient has been dosed in the IDeate-Esophageal01 phase 3 trial evaluating the effi...
   READ ARTICLE

3. Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society's (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension

   Business Wire MAY 16, 2025 6:45 AM EDT
   P reliminary results from a pooled analysis of clinical trial data evaluating the long-term s...
   READ ARTICLE

4. Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers

   Business Wire MAY 15, 2025 6:45 AM EDT
   Study also met secondary endpoint of overall survival (OS) for patients whose tumors express PD-L...
   READ ARTICLE

5. FDA Approves Merck's WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)

   Business Wire MAY 14, 2025 5:15 PM EDT
   WELIREG becomes the only approved and available treatment in the U.S. for eligible patients with ...
   READ ARTICLE

6. Research on Novel Treatment Approaches and Scientific Advances From Merck's Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025

   Business Wire MAY 13, 2025 6:45 AM EDT
   New and updated data for MK-1084, an investigational KRAS G12C inhibitor, from the colorectal...
   READ ARTICLE

7. Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal

   GlobeNewswire MAY 12, 2025 1:00 AM EDT
   Paris, May 12 , 2025 - Jeito Capital (“Jeito”), a global leading independ...
   READ ARTICLE

8. Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto

   Business Wire MAY 8, 2025 6:45 AM EDT
   Merck Animal Health unveils its largest economic development project in recent history ...
   READ ARTICLE

9. Merck to Participate in the Bank of America 2025 Global Healthcare Conference

   Business Wire MAY 7, 2025 6:45 AM EDT
   Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jan...
   READ ARTICLE

10. Kuehn Law Encourages Investors of Merck & Co., Inc. to Contact Law Firm

    Newsfile MAY 1, 2025 4:47 PM EDT
    New York, New York--(Newsfile Corp. - May 1, 2025) - Kuehn Law, PLLC, a shareholder litigation la...
    READ ARTICLE